The award recognizes Dr. Torlakovic’s leadership in quality assurance through her work in several areas around quality improvement and diagnostic testing. She is co-founder of the Canadian Immunohistochemistry Quality Control (cIQc), the first national external quality assurance (EQA) program that offers proficiency testing in immunohistochemistry (IHC) to all Canadian IHC laboratories. This is a unique academic EQA program that specializes in cancer biomarkers testing.
She is the Chair of the National Standards Committee for High Complexity Testing which published the first Canadian guidelines for standardization of immunohistochemistry testing in Pathology. This committee also developed and published other recommendations and guidelines including: CAP-ACP Clinical Immunohistochemistry Checklists: Part I and Part II, Guidelines for the Preparation, Release, and Storage of Unstained Archived Diagnostic Tissue Sections for Immunohistochemistry, and Class II IHC Checklist for MMR IHC Testing.
“I thought it was very important that we develop standards because today we are called upon for much higher accuracy in IHC, mainly driven by the development of personalized medicine,” said Dr. Torlakovic. “We try to respond and develop highly reproducible, sensitive and specific testing relevant to the stratification of patients for targeted therapies.”
Dr. Torlakovic received the award on Tuesday July 15 at the Gala Banquet and Awards reception, during the CAP-ACP conference in Toronto.